奥西替尼联合吉西他滨治疗伴肾转移的老年晚期NSCLC患者的临床疗效

doi:10.3969/j.issn.1671-7171.2024.07.016

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1264 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨奥西替尼联合吉西他滨治疗伴肾转移的老年晚期非小细胞肺癌(NSCLC)患者的临床疗效。【方法】本院收治的238例老年晚期NSCLC患者,随机分为对照组和观察组,每组119例。对照组给予奥西替尼治疗,观察组在此基础上另给予顺铂、吉西他滨治疗。比较两组治疗3个疗程后的疗效及治疗前后肿瘤标志物、肾功能指标的变化,药物安全性和1年生存情况。【结果】观察组临床控制率高于对照组(P<0.05)。两组治疗后癌胚抗原(CEA)、胃泌素释放肽前体(ProGRP)、鳞状细胞癌抗原(SCCA)水平较治疗前均降低(P<0.05),且观察组CEA、ProGRP、SCCA均低于对照组(P<0.05)。两组治疗前后的血尿素氮、血肌酐水平比较,差异均无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。观察组1年总存活曲线优于对照组(P<0.05)。【结论】奥西替尼联合吉西他滨方案治疗伴肾转移的老年晚期NSCLC患者疗效显著,可降低肿瘤标志物水平,延长患者近期生存时间,且安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王惠
	贾靖
	王辉

关键词 ：癌,非小细胞肺, 脱氧胞苷/治疗应用, 肿瘤转移, 治疗结果

Abstract：【Objective】 To investigate the clinical efficacy and survival status of osimertinib combined with gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) and renal metastasis. 【Methods】 A total of 238 elderly patients with advanced NSCLC admitted to our hospital were randomly divided into the control group and the observation group, with 119 cases in each group. The control group was treated with osimertinib, while the observation group was additionally treated with cisplatin and gemcitabine. The efficacy after 3 treatment cycles, changes in tumor markers and renal function indicators before and after treatment, drug safety, and 1-year survival status were compared between the two groups. 【Results】 The clinical control rate in the observation group was higher than that in the control group (P<0.05). After treatment, the levels of carcinoembryonic antigen (CEA), pro-gastrin-releasing peptide (ProGRP), and squamous cell carcinoma antigen (SCCA) were lower in both groups compared to before treatment (P<0.05), with the observation group showing even lower levels than the control group (P<0.05). There were no significant differences in blood urea nitrogen and serum creatinine levels between the two groups before and after treatment (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The 1-year overall survival curve of the observation group was better than that of the control group (P<0.05). 【Conclusion】 The treatment regimen of osimertinib combined with gemcitabine for elderly patients with advanced NSCLC and renal metastasis is significantly effective,which can reduce tumor markers, provide short-term survival benefits, and has good safety.

Key words： Carcinoma, Non-Small-Cell Lung Deoxycytidine/TU Neoplasm Metastasis Treatment Outcome

收稿日期: 2023-08-01

中图分类号:

R734.2

引用本文:

王惠, 贾靖, 王辉. 奥西替尼联合吉西他滨治疗伴肾转移的老年晚期NSCLC患者的临床疗效[J]. 医学临床研究, 2024, 41(7): 1017-1019.
WANG Hui, JIA Jing, WANG Hui. Clinical Efficacy of Osimertinib Combined with Gemcitabine in the Treatment of Elderly Patients with Advanced NSCLC and Renal Metastasis. JOURNAL OF CLINICAL RESEARCH, 2024, 41(7): 1017-1019.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.07.016 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I7/1017

[1] SVATON M. Targeted therapy of non-small cell lung cancer[J].Klin Onkol,2021, 34(1):48-52.
[2] BARAN K, BRZEZIAЍSKA-LASOTA E. Proteomic biomarkers of non-small cell lung cancer patients[J].Adv Respir Med,2021, 89(4):419-426.
[3] MEADOR C B, SEQUIST L V, PIOTROWSKA Z. Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates[J].Cancer Discov,2021,11(9):2145-2157.
[4] TSUBOI M, WEDER W, ESCRIU C, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer:NeoADAURA[J].Future Oncol,2021, 17(31):4045-4055.
[5] CHO B C, FELIP E, HAYASHI H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer[J].Future Oncol,2022, 18(6):639-647.
[6] ETTINGER D S, WOOD D E, AISNER D L, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021[J].J Natl Compr Canc Netwr,2021, 19(3):254-266.
[7] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2):228-247.
[8] GOOSEMAN M R, BRUNELLI A. Intraoperative lymph node management during non-small cell lung cancer surgery[J].Ann Surg Oncol,2021, 28(12):6925-6926.
[9] REMON J, SORIA J C, PETERS S, et al. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy[J].Ann Oncol,2021, 32(12):1637-1642.
[10] WU Y L, TSUBOI M, JOHN T, et al. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer[J].Future Oncol,2021, 17(35):4827-4835.
[11] YU H A, GOLDBERG S B, LE X, et al. Biomarker-Directed phase Ⅱ platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)[J].Clin Lung Cancer,2021, 22(6):601-606.
[12] 吴皓, 李萍. 奥希替尼联合放化疗治疗晚期非小细胞肺癌患者的临床疗效及安全性分析[J].中国肿瘤临床与康复, 2020, 27(4):400-403.